Benralizumab is noninferior to mepolizumab in achieving remission of relapsing or refractory eosinophilic granulomatosis with polyangiitis at 36 and 48 weeks, according to data published in The ...

Benralizumab resulted in a 45-51% reduction in exacerbation rates compared to placebo (reduction from 3.0 to 0.73 per year for treatment every 4 weeks; ...

Gastroenterology > General Gastroenterology Benralizumab Led to Histologic Responses in Eosinophilic Esophagitis — But there was no significant difference in symptom relief compared with placebo ...

Benralizumab is an anti-eosinophil monoclonal antibody that induces direct, rapid and near-complete depletion of eosinophils, with an onset of action within 24 hours as confirmed in early phase I ...

At both weeks 36 and 48, the benralizumab group exhibited an adjusted remission rate of 59.2%, while the mepolizumab group demonstrated a rate of 56.5% (difference, 2.71%; 95% CI, -12.54 to 17.96 ...

BOSTON — Patients taking benralizumab experienced more asthma exacerbations than patients taking mepolizumab, according to an abstract presented at the CHEST Annual Meeting. This study compared ...

SAN DIEGO — Benralizumab reduces exacerbations and improves lung function in asthma patients with elevated eosinophil counts, according to a phase 2 trial. Some patients with severe asthma fail ...

Benralizumab is a type of drug called an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody. It is approved by the FDA for the treatment of severe eosinophilic asthma.

A year's course of benralizumab injections has led to a significant decrease in the frequency of asthma exacerbations -- cutting the rate of exacerbations by a third to a half compared with ...

Benralizumab, an interleukin-5 (IL-5) antagonist used to treat severe asthma, does not weaken antibody response of influenza vaccinations, according to results of a recent study.

AstraZeneca announced top-line results from two pivotal Phase 3 studies for benralizumab as adjunct to standard-of-care therapy for the treatment of severe asthma with an eosinophilic phenotype ...

A year's course of benralizumab injections has led to a significant decrease in the frequency of asthma exacerbations - cutting the rate of exacerbations by a third to a half compared with placebo ...